protocolSection identificationModule nctId: NCT06345027, orgStudyIdInfo id: H-53163 CASEY, briefTitle: CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY), acronym: CASEY, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-05-01, completionDateStruct date: 2042-04-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Baylor College of Medicine, class: OTHER, descriptionModule briefSummary: This study is for patients that have lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T/NK-lymphoproliferative disease and the patients condition has come back or has not gone away after treatment, including the best treatment we know for these diseases.Some patients with Lymphoma or T/NK-lymphoproliferative disease show signs of virus that is sometimes called Epstein Barr virus (EBV). This virus causes mononucleosis or glandular fever ("mono") before or at the time of their diagnosis. EBV is found in the cancer cells of up to half the patients with Hodgkin's and non-Hodgkin Lymphoma. This suggests that the EBV plays a role in causing Lymphoma. The cancer cells (in lymphoma) and some immune system cells infected by EBV are able to hide from the body's immune system and escape destruction.T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. T cells have been used to treat patients with cancers. T cells, that have been trained to kill EBV infected cells can survive in blood and affect the tumor. We have treated over 80 people on studies using T cells to target these diseases. About half of those patients who had disease at the time they got the cells had responses including some patients with complete responses (meaning the cancer could no longer be detected).We think that if T cells are able to last longer in the body, they may have a better chance of killing EBV and EBV infected tumor cells. Therefore, in this study we will add a new gene to the EBV T cells that can cause the cells to live longer called C7R. We know that T cells need substances called cytokines (substances such as proteins released by specific cells of the immune system) to survive and that the cells may not get enough cytokines after the cells are infused into the body. We have added the gene C7R that gives the cells a constant supply of cytokine and helps them to survive for a longer period of time.The purpose of this study is to find the largest safe dose of C7R-EBV T cells, and additionally to evaluate how long they can be detected in the blood and what affect they have on the cancer., conditionsModule conditions: Leukemia, Myeloid, Acute, conditions: Leukemia, B-cell, conditions: Leukemia, T-Cell, conditions: Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Treatment Arm A, outcomesModule primaryOutcomes measure: Dose limiting toxicity (DLT) rate, secondaryOutcomes measure: Overall Response Rate, eligibilityModule sex: ALL, maximumAge: 75 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Texas Children's Hospital, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Bilal Omer, MD, role: CONTACT, phone: 832-826-0860, email: baomer@texaschildrens.org, geoPoint lat: 29.76328, lon: -95.36327, locations facility: The Methodist Hospital, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Bilal Omer, MD, role: CONTACT, phone: 832-826-0860, email: baomer@texaschildrens.org, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False